Meeting
2018 Gastrointestinal Cancers Symposium
Second-line chemotherapy for gallbladder cancer.
Authors
Nicha Wongjarupong
Mayo Clinic, Rochester, MN
Nicha Wongjarupong , Mohamed Abdelrahim Muddathir Hassan , Cristobal T. Sanhueza , Mindy L. Hartgers , Fatima Hassan , Lewis R. Roberts , Amit Mahipal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 450)
DOI
10.1200/JCO.2018.36.4_suppl.450
Abstract #
450
Poster Bd #
L21
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Long-term responders to palliative chemotherapy for advanced biliary tract cancer.
First Author: Mark Doherty
Poster
2014 Gastrointestinal Cancers Symposium
Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma.
First Author: Jose Luis Leal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.
First Author: Angela Lamarca
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu